-
Spinal gap: Neuralstem goes into chronic injuries phase I, first ever cleared by FDA
Neuralstem’s President and CEO, Richard Garr, is interviewed in this cover story reporting on the promise of Neuralstem’s NSI-566/chronic spinal cord injury (cSCI) Phase I trial, now underway at the University of California, San Diego School of Medicine. This trial, like Neuralstem’s ongoing NSI-566/ALS trials, represents the first FDA-approved stem cell trial for the indication. While both trials use the same cells and similar procedure, Mr. Garr explains that in addition to neurotrophic factors, in spinal cord injury patients the NSI-566 mechanism of action includes rebuilding neural circuitry for structural repair, “literally bridging the gap… trying to rebuild the circuitry in the gap so that the signal can come through, down the spinal cord.”
